The pharmacology of experimental myopathies.
D015084:2,4-Dichlorophenoxyacetic Acid / Q000494:pharmacology; D000818:Animals; D001001:Anura; D001679:Biogenic Amines / Q000494:pharmacology; D002784:Cholesterol / Q000031:analogs & derivatives / Q000494:pharmacology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D002802:Cholinesterases / Q000378:metabolism; D004195:Disease Models, Animal; D004789:Enzyme Activation / Q000187:drug effects; D006041:Goats; D006801:Humans; D008026:Ligation; D008564:Membrane Potentials; D009132:Muscles / Q000098:blood supply / Q000503:physiopathology / Q000648:ultrastructure; D009135:Muscular Diseases / Q000139:chemically induced* / Q000503:physiopathology; D009136:Muscular Dystrophies / Q000139:chemically induced; D009222:Myotonia / Q000139:chemically induced / Q000503:physiopathology; D009420:Nervous System / Q000503:physiopathology; D009468:Neuromuscular Diseases / Q000139:chemically induced; D018377:Neurotransmitter Agents / Q000378:metabolism; D051381:Rats; D012701:Serotonin / Q000494:pharmacology; D013997:Time Factors
D001679:Biogenic Amines; D002800:Cholinesterase Inhibitors; D018377:Neurotransmitter Agents; D015084:2,4-Dichlorophenoxyacetic Acid; D012701:Serotonin; D002784:Cholesterol; D002802:Cholinesterases